Phase II trial of trimelamol in refractory ovarian cancer.

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using t...

Descripción completa

Detalles Bibliográficos
Autores principales: Judson, I. R., Calvert, A. H., Gore, M. E., Balmanno, K., Gumbrell, L. A., Perren, T., Wiltshaw, E.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1991
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971798/
https://www.ncbi.nlm.nih.gov/pubmed/1997112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971798/
https://www.ncbi.nlm.nih.gov/pubmed/1997112

Ejemplares similares